/ /

Lynda Charters
Two-stage, well-tolerated procedure for inlay ensures refractive stability
The optimal time of implantation of a corneal inlay (Kamra, AcuFocus) to correct presbyopia in ametropic presbyopic patients seems to be 1 week after traditional LASIK in a planned two-stage KAMRA procedure.
MIGS study: Role of two stents for IOP
Implantation of two stents (iStent, Glaukos) may be another option for controlling IOP in phakic and pseudophakic patients with open-angle glaucoma who are refractory to one anti-glaucoma medication.
Near, intermediate vision with inlay maintained over the long-term
A corneal inlay improves near and intermediate vision with minimal compromise in distance acuity. Results are maintained over the long-term.
SLT effective part of glaucoma care strategy in developing countries
Selective laser trabeculoplasty provided a majority of Afro-Caribbean patients with a mean IOP reduction of 40% with no need for medical therapy.
Why balanced tip increases phaco with less energy
A new surgical advance—the Intrepid Balanced phacotips designed specifically for microcoaxial torsional ultrasound—has been found to have a significantly increased emulsification effect and markedly reduced shaft action compared with the traditional Kelman flared and mini-tips, said Khiun Tjia, MD.
Oral vs. IV steroids for giant cell arteritis
Intravenous methylprednisolone may prevent visual loss and occasionally achieve visual recovery in patients with giant cell arteritis.
Examining advances in AAV vector for retinal gene therapy
Much work is being done with Adeno-associated virus (AAV) vectors for application in retinal gene therapy, with modifications being made to the capsid and genome of the vector to generate novel variants with unique transduction profiles, according to Shannon Boye, PhD.
RIDE, RISE phase III results favorable for DME treatment
RIDE, RISE phase III results favorable for DME treatment
The open-label extension RIDE and RISE phase III studies of ranibizumab (Lucentis, Genentech) indicated that the beneficial results of the drug for treating diabetic macular edema were maintained over the long-term with less than monthly follow-up or injection treatment.
Examining 1-year LUCAS Study results for AMD treatments
The 1-year results of the inject-and-extend Lucentis Compared to Avastin Study (Lucas) for exudative age-related macular degeneration (AMD) indicated that the two drugs have equivalent effectiveness, said Karina Berg, MD.
Future of uveitis therapy takes shape with new treatments
Potentially effective new drugs are in the pipeline for treating uveitis, in addition to several promising formulations in clinical trials.


View Results